CWM
HALO icon

Cranbrook Wealth Management’s Halozyme HALO Stock Holding History

Cranbrook Wealth Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13
Closed -$622 – 440
2024
Q4 		$622 Hold
13
– – ﹤0.01% 378
2024
Q3 		$745 Buy
+13
New +$745 ﹤0.01% 346

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cranbrook Wealth Management's HALO Position: Q1 2025 in Review

Cranbrook Wealth Management sold out of Halozyme (HALO) in Q1 2025, closing a stake of 13 shares — an estimated $622 sold.

Cranbrook Wealth Management first reported a position in HALO in Q3 2024 and held it in 2 quarters. The position peaked at $745 in Q3 2024. 550 funds tracked by Wall St. Rank hold HALO as of Q1 2025.

  • Cranbrook Wealth Management reported no remaining Halozyme position as of Q1 2025 after selling out during the quarter.
  • Cranbrook Wealth Management sold 13 Halozyme shares in Q1 2025, an estimated $622.
  • Cranbrook Wealth Management first reported a position in Halozyme in Q3 2024 and held it in 2 quarters.
  • Cranbrook Wealth Management's Halozyme position peaked at $745 in Q3 2024.
  • 550 funds tracked by Wall St. Rank held Halozyme as of Q1 2025.

Based on Cranbrook Wealth Management's 13F filing for Q1 2025, filed 11 Apr 2025.